Centers | ||
|
|
|
EU-OPENSCREEN | BLAVATNIK CENTER for Drug Discovery | Saint Louis University Institute for Drug and Biotherapeutic Innovation (IDBI) |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
The BLAVATNIK CENTER for Drug Discovery (BCDD) is a fully integrated center for translational research, based at Tel Aviv University, that comprises medicinal chemistry, biological target identification and computer-assisted drug design units under... Read more |
The IDBI is a decentralized, collaborative institute whose mission is to promote the translation of research projects at Saint Louis University through drug discovery and pre-clinical development. The IDBI achieves this through four main... |
Partnerships |
Events |
Jobs |
GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all Johnson & Johnson to Support Pain Research at Queensland UniversityJohnson & Johnson and Institute for Molecular Bioscience (IMB) at University of Queensland have entered into research agreement to develop peptides using IMB's novel assay to treat chronic pain. Johnson & Johnson and its affiliates will provide... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
